Dr. Pastan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
national cancer institute
37 convent lane
Bethesda, MD 20892Phone+1 240-760-6470- Is this information wrong?
Education & Training
Tufts University School of MedicineClass of 1957
Awards, Honors, & Recognition
- Elected Member Institute of Medicine, 2010
- Whos Who in Medicine and Healthcare Marquis Whos Who
Clinical Trials
- LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors Start of enrollment: 1998 May 01
Publications & Presentations
PubMed
- 12 citationsImmunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urineXui Fen Liu, Junxia Wei, Qi Zhou, Bruce A. Molitoris, Ruben M. Sandoval, Hisataka Kobayashi, Ryuhei Okada, Tadanobu Nagaya, Baktiar Karim, Donna Butcher, Ira Pastan> ;Proceedings of the National Academy of Sciences of the United States of America. 2020 Mar 17
- 12 citationsSite-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor ActivityZeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai, Ira Pastan> ;Molecular Cancer Therapeutics. 2020 Mar 1
- 8 citationsAnti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal CancerAdam Cerise, Tapan K. Bera, Xiu-fen Liu, Junxia Wei, Ira Pastan> ;Clinical Colorectal Cancer. 2019 Jul 2
- Join now to see all
Abstracts/Posters
- Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 TrialIra Pastan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Molecular Remissions with Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox Are Associated with Improved Complete Remission Durations during Phase I and III Testing2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Biologic Therapeutics Seminar Series - Systems Approaches to Antibody-based Immunotherapy of CancerWashington University School of Medicine, Saint Louis, Missouri - 5/16/2012
Press Mentions
NCI Opens New Immunotherapy Clinical Trial for MesotheliomaJanuary 4th, 2022- NCI Studying New Mesothelioma Immunotherapy CombinationJuly 8th, 2020
US FDA Approves LUMOXITI™ (Moxetumomab Pasudotox-Tdfk) for Certain Patients with Relapsed or Refractory Hairy Cell LeukemiaSeptember 13th, 2018
Grant Support
- Growth Regulation SectionNational Cancer Institute2008
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: Preclinical StudiesNational Cancer Institute2007–2008
- Gene DiscoveryNational Cancer Institute2007
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: PDivision Of Basic Sciences - Nci2002–2006
- Gene DiscoveryDivision Of Basic Sciences - Nci1998–2006
- Immunotoxin Therapy Of Solid And Hematopoietic TumorsDivision Of Basic Sciences - Nci2003–2004
- Immunotoxin Therapy In CancerDivision Of Basic Sciences - Nci2001
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: Preclinical StudiesDivision Of Basic Sciences - Nci2000
- Immunotoxin Therapy Of Solid And Hematopoietic Tumors: Preclinical StudiesDivision Of Basic Sciences - Nci1999
- Immunotoxin Therapy Of OLID Tumors--Preclinical StudiesDivision Of Basic Sciences - Nci1997–1998
- Immunotoxins And Recombinant Toxin Therapy Of CancerDivision Of Basic Sciences - Nci1996
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
